Protalix BioTherapeuticsPLX
Market Cap: $84.2M
About: Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Employees: 208
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,400% more call options, than puts
Call options by funds: $125K | Put options by funds: $5K
3% more funds holding
Funds holding: 62 [Q1] → 64 (+2) [Q2]
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
1.91% less ownership
Funds ownership: 9.57% [Q1] → 7.66% (-1.91%) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 16
46% less capital invested
Capital invested by funds: $12.1M [Q1] → $6.57M (-$5.55M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for PLX.
Financial journalist opinion
Based on 4 articles about PLX published over the past 30 days